John G Webb1, Darshan Doshi2, Michael J Mack3, Raj Makkar4, Craig R Smith2, Augusto D Pichard5, Susheel Kodali2, Samir Kapadia6, D Craig Miller7, Vasilis Babaliaros8, Vinod Thourani8, Howard C Herrmann9, Mark Bodenhamer10, Brian K Whisenant11, Stephen Ramee12, Hersh Maniar13, Dean Kereiakes14, Ke Xu15, Wael A Jaber6, Venu Menon6, E Murat Tuzcu6, David Wood16, Lars G Svensson6, Martin B Leon2. 1. St. Paul's Hospital, Vancouver, British Columbia, Canada. Electronic address: john.webb@vch.ca. 2. Columbia University Medical Center, New York, New York. 3. Baylor Scott & White Health, Plano, Texas. 4. Cedars Sinai Medical Center, Los Angeles, California. 5. Medstar Washington Hospital Center, Washington, DC. 6. Cleveland Clinic, Cleveland, Ohio. 7. Stanford University, Stanford, California. 8. Emory University School of Medicine, Atlanta, Georgia. 9. Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 10. Oklahoma Heart Hospital, Oklahoma City, Oklahoma. 11. Intermountain Medical Center, Salt Lake City, Utah. 12. Ochsner Clinic, New Orleans, Louisiana. 13. Washington University School of Medicine, Saint Louis, Missouri. 14. The Christ Hospital, Cincinnati, Ohio. 15. Cardiovascular Research Foundation, New York, New York. 16. St. Paul's Hospital, Vancouver, British Columbia, Canada.
Abstract
OBJECTIVES: The purpose of this study was to determine the safety and effectiveness of the SAPIEN XT versus SAPIEN systems (Edwards Lifesciences, Irvine, California) in patients with symptomatic, severe aortic stenosis (AS) who were not candidates for surgery. BACKGROUND:Transcatheter aortic valve replacement (TAVR) has become the standard of care for inoperable patients with severe, symptomatic AS. In the PARTNER (Placement of Aortic Transcatheter Valves) IB trial, a reduction in all-cause mortality was observed in patients undergoing TAVR with the balloon-expandable SAPIEN transcatheter heart valve compared with standard therapy, but the SAPIEN valve was associated with adverse periprocedural complications, including vascular complications, major bleeding, and paravalvular regurgitation. The newer, low-profile SAPIEN XT system was developed to reduce these adverse events. METHODS: A total of 560 patients were enrolled at 28 sites in the United States from April 2011 to February 2012. Patients were randomized to receive the SAPIEN or SAPIEN XT systems. The primary endpoint was a nonhierarchical composite of all-cause mortality, major stroke, and rehospitalization at 1 year in the intention-to-treat population, assessed by noninferiority testing. Pre-specified secondary endpoints included cardiovascular death, New York Heart Association functional class, myocardial infarction, stroke, acute kidney injury, vascular complications, bleeding, 6-min walk distance, and valve performance (by echocardiography). RESULTS: Both overall and major vascular complications were higher at 30 days in patients undergoing TAVR with SAPIEN compared with SAPIEN XT (overall: 22.1% vs. 15.5%; p = 0.04; major: 15.2% vs. 9.5%; p = 0.04). Bleeding requiring blood transfusions was also more frequent with SAPIEN compared with SAPIEN XT (10.6% vs. 5.3%; p = 0.02). At 1-year follow-up, the nonhierarchical composite of all-cause mortality, major stroke, or rehospitalization was similar (37.7% SAPIEN vs. 37.2% SAPIEN XT; noninferiority p value <0.002); no differences in the other major pre-specified endpoints were found. CONCLUSIONS: In inoperable patients with severe, symptomatic AS, the lower-profile SAPIEN XT is noninferior to SAPIEN with fewer vascular complications and a lesser need for blood transfusion. (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves; NCT01314313).
RCT Entities:
OBJECTIVES: The purpose of this study was to determine the safety and effectiveness of the SAPIEN XT versus SAPIEN systems (Edwards Lifesciences, Irvine, California) in patients with symptomatic, severe aortic stenosis (AS) who were not candidates for surgery. BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become the standard of care for inoperable patients with severe, symptomatic AS. In the PARTNER (Placement of Aortic Transcatheter Valves) IB trial, a reduction in all-cause mortality was observed in patients undergoing TAVR with the balloon-expandable SAPIEN transcatheter heart valve compared with standard therapy, but the SAPIEN valve was associated with adverse periprocedural complications, including vascular complications, major bleeding, and paravalvular regurgitation. The newer, low-profile SAPIEN XT system was developed to reduce these adverse events. METHODS: A total of 560 patients were enrolled at 28 sites in the United States from April 2011 to February 2012. Patients were randomized to receive the SAPIEN or SAPIEN XT systems. The primary endpoint was a nonhierarchical composite of all-cause mortality, major stroke, and rehospitalization at 1 year in the intention-to-treat population, assessed by noninferiority testing. Pre-specified secondary endpoints included cardiovascular death, New York Heart Association functional class, myocardial infarction, stroke, acute kidney injury, vascular complications, bleeding, 6-min walk distance, and valve performance (by echocardiography). RESULTS: Both overall and major vascular complications were higher at 30 days in patients undergoing TAVR with SAPIEN compared with SAPIEN XT (overall: 22.1% vs. 15.5%; p = 0.04; major: 15.2% vs. 9.5%; p = 0.04). Bleeding requiring blood transfusions was also more frequent with SAPIEN compared with SAPIEN XT (10.6% vs. 5.3%; p = 0.02). At 1-year follow-up, the nonhierarchical composite of all-cause mortality, major stroke, or rehospitalization was similar (37.7% SAPIEN vs. 37.2% SAPIEN XT; noninferiority p value <0.002); no differences in the other major pre-specified endpoints were found. CONCLUSIONS: In inoperable patients with severe, symptomatic AS, the lower-profile SAPIEN XT is noninferior to SAPIEN with fewer vascular complications and a lesser need for blood transfusion. (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves; NCT01314313).
Authors: Jayendrakumar S Patel; Amar Krishnaswamy; Lars G Svensson; E Murat Tuzcu; Stephanie Mick; Samir R Kapadia Journal: Curr Cardiol Rep Date: 2016-11 Impact factor: 2.931
Authors: Brian R Lindman; Marie-Annick Clavel; Patrick Mathieu; Bernard Iung; Patrizio Lancellotti; Catherine M Otto; Philippe Pibarot Journal: Nat Rev Dis Primers Date: 2016-03-03 Impact factor: 52.329
Authors: Ashkan Karimi; Negiin Pourafshar; Ki E Park; Calvin Y Choi; Kiran Mogali; Wade W Stinson; Eddie W Manning; Anthony A Bavry Journal: Cardiol Ther Date: 2017-01-02
Authors: Philipp C Seppelt; Silvia Mas-Peiro; Roberta De Rosa; Zisis Dimitriasis; Andreas M Zeiher; Mariuca Vasa-Nicotera Journal: Clin Res Cardiol Date: 2020-11-29 Impact factor: 5.460
Authors: Thomas Pilgrim; Joe K T Lee; Crochan J O'Sullivan; Stefan Stortecky; Sara Ariotti; Anna Franzone; Jonas Lanz; Dik Heg; Masahiko Asami; Fabien Praz; George C M Siontis; René Vollenbroich; Lorenz Räber; Marco Valgimigli; Eva Roost; Stephan Windecker Journal: Open Heart Date: 2018-01-20
Authors: Philippe Généreux; Philippe Pibarot; Björn Redfors; Michael J Mack; Raj R Makkar; Wael A Jaber; Lars G Svensson; Samir Kapadia; E Murat Tuzcu; Vinod H Thourani; Vasilis Babaliaros; Howard C Herrmann; Wilson Y Szeto; David J Cohen; Brian R Lindman; Thomas McAndrew; Maria C Alu; Pamela S Douglas; Rebecca T Hahn; Susheel K Kodali; Craig R Smith; D Craig Miller; John G Webb; Martin B Leon Journal: Eur Heart J Date: 2017-12-01 Impact factor: 29.983